StreetInsider.com News Articles

Drew Brees Collaborates with ARS Pharmaceuticals to Raise Awareness About Living Life with Severe Allergies

Thu, 04 Jun 2026 08:00:00 -0400

Former NFL quarterback and 2026 Hall of Fame inductee highlights daily life for people living with severe food allergies and role preparedness plays in living fully

Collaboration focuses on education around the importance of epinephrine and treatment options for severe allergic reactions, including anaphylaxis

SAN DIEGO, June 04, 2026 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering patients and their caregivers to better protect against allergic reactions that could lead to anaphylaxis, today announced a new collaboration with Drew Brees, former NFL quarterback, Super Bowl champion, 2026

Drew Brees Collaborates with ARS Pharmaceuticals to Raise Awareness About Living Life with Severe Allergies

Thu, 04 Jun 2026 08:00:00 -0400

Former NFL quarterback and 2026 Hall of Fame inductee highlights daily life for people living with severe food allergies and role preparedness plays in living fully

Collaboration focuses on education around the importance of epinephrine and treatment options for severe allergic reactions, including anaphylaxis

Form 3 ARS Pharmaceuticals, For: Jun 01 Filed by: Casale Donn

Mon, 01 Jun 2026 16:42:00 -0400

si-local-file:///var/storage/secattach/20260601/26584496.html

Form 3 ARS Pharmaceuticals, For: Jun 01 Filed by: Casale Donn

Mon, 01 Jun 2026 16:42:00 -0400

si-local-file:///var/storage/secattach/20260601/26584496.html

ARS Pharmaceuticals Inc (SPRY) PT Raised to $30 at Cantor Fitzgerald

Fri, 29 May 2026 07:00:40 -0400

Cantor Fitzgerald analyst Josh Schimmer raised the price target on ARS Pharmaceuticals Inc (NASDAQ: SPRY) to $30.00 (from $12.00) while maintaining an Overweight rating.

The analyst commented, "We hosted a webinar to provide a more in-depth review of our work on SPRY's clinical program for CSU flares following our report yesterday. We believe this program represents a differentiated and under-appreciated opportunity that warrants greater investor attention. Based on our analysis and checks, we have a high degree of conviction in its likelihood of success. In this webinar, we walk through the pathophysiology of CSU, discuss limitations in the current treatment options

ARS Pharmaceuticals Inc (SPRY) PT Raised to $30 at Cantor Fitzgerald

Fri, 29 May 2026 07:00:40 -0400

Cantor Fitzgerald analyst Josh Schimmer raised the price target on ARS Pharmaceuticals Inc (NASDAQ: SPRY) to $30.00 (from $12.00) while maintaining an Overweight rating.

Form SCHEDULE 13G/A ARS Pharmaceuticals, Filed by: Rubric Capital Management LP

Fri, 15 May 2026 16:15:00 -0400

si-local-file:///var/storage/secattach/20260515/26505476.html

Form SCHEDULE 13G/A ARS Pharmaceuticals, Filed by: Rubric Capital Management LP

Fri, 15 May 2026 16:15:00 -0400

si-local-file:///var/storage/secattach/20260515/26505476.html

Form 10-Q ARS Pharmaceuticals, For: Mar 31

Fri, 15 May 2026 06:18:00 -0400

si-local-file:///var/storage/secattach/20260515/26498763.html

Form 10-Q ARS Pharmaceuticals, For: Mar 31

Fri, 15 May 2026 06:18:00 -0400

si-local-file:///var/storage/secattach/20260515/26498763.html

Form 8-K ARS Pharmaceuticals, For: May 15

Fri, 15 May 2026 06:15:00 -0400

si-local-file:///var/storage/secattach/20260515/26498623.html

Form 8-K ARS Pharmaceuticals, For: May 15

Fri, 15 May 2026 06:15:00 -0400

si-local-file:///var/storage/secattach/20260515/26498623.html

ARS Pharmaceuticals, Inc. (SPRY) Misses Q1 EPS by 12c, Beats on Revenue

Fri, 15 May 2026 06:01:45 -0400

ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) reported Q1 EPS of ($0.61), $0.12 worse than the analyst estimate of ($0.49). Revenue for the quarter came in at $22.7 million versus the consensus estimate of $22.67 million.

For earnings history and earnings-related data on ARS Pharmaceuticals, Inc. (SPRY) click here.

ARS Pharmaceuticals Reports First Quarter 2026 Financial Results and Corporate Update

Fri, 15 May 2026 06:00:00 -0400

Q1 2026 total revenue of $22.7 million including neffy® (epinephrine nasal spray) U.S. net product
revenue of $17.5 million

CVS Caremark proposal in final stages of approval process; definitive update anticipated in early June

Sales force expansion to 148 representatives completed

Phase 2b CSU study interim population fully enrolled, and on track for Q4 2026 readout

Conference call to be held today, May 15, 2026, at 5:30 a.m. PT / 8:30 a.m. ET

SAN DIEGO, May 15, 2026 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a

ARS Pharmaceuticals Reports First Quarter 2026 Financial Results and Corporate Update

Fri, 15 May 2026 06:00:00 -0400

Q1 2026 total revenue of $22.7 million including neffy® (epinephrine nasal spray) U.S. net product
revenue of $17.5 million

CVS Caremark proposal in final stages of approval process; definitive update anticipated in early June

Sales force expansion to 148 representatives completed

Phase 2b CSU study interim population fully enrolled, and on track for Q4 2026 readout

Conference call to be held today, May 15, 2026, at 5:30 a.m. PT / 8:30 a.m. ET

SAN DIEGO, May 15, 2026 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a

ARS Pharmaceuticals Reports First Quarter 2026 Financial Results and Corporate Update

Fri, 15 May 2026 06:00:00 -0400

Q1 2026 total revenue of $22.7 million including neffy® (epinephrine nasal spray) U.S. net product
revenue of $17.5 million

CVS Caremark proposal in final stages of approval process; definitive update anticipated in early June

Sales force expansion to 148 representatives completed

Phase 2b CSU study interim population fully enrolled, and on track for Q4 2026 readout

Conference call to be held today, May 15, 2026, at 5:30 a.m. PT / 8:30 a.m. ET

SAN DIEGO, May 15, 2026 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a

ARS Pharmaceuticals Reports First Quarter 2026 Financial Results and Corporate Update

Fri, 15 May 2026 06:00:00 -0400

Q1 2026 total revenue of $22.7 million including neffy® (epinephrine nasal spray) U.S. net product
revenue of $17.5 million

CVS Caremark proposal in final stages of approval process; definitive update anticipated in early June

Sales force expansion to 148 representatives completed

Phase 2b CSU study interim population fully enrolled, and on track for Q4 2026 readout

Conference call to be held today, May 15, 2026, at 5:30 a.m. PT / 8:30 a.m. ET

SAN DIEGO, May 15, 2026 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a

ARS Pharmaceuticals Reports First Quarter 2026 Financial Results and Corporate Update

Fri, 15 May 2026 06:00:00 -0400

Q1 2026 total revenue of $22.7 million including neffy® (epinephrine nasal spray) U.S. net product
revenue of $17.5 million

CVS Caremark proposal in final stages of approval process; definitive update anticipated in early June

Sales force expansion to 148 representatives completed

Phase 2b CSU study interim population fully enrolled, and on track for Q4 2026 readout

Conference call to be held today, May 15, 2026, at 5:30 a.m. PT / 8:30 a.m. ET

SAN DIEGO, May 15, 2026 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a

ARS Pharmaceuticals Reports First Quarter 2026 Financial Results and Corporate Update

Fri, 15 May 2026 06:00:00 -0400

Q1 2026 total revenue of $22.7 million including neffy® (epinephrine nasal spray) U.S. net product
revenue of $17.5 million

CVS Caremark proposal in final stages of approval process; definitive update anticipated in early June

Sales force expansion to 148 representatives completed

Phase 2b CSU study interim population fully enrolled, and on track for Q4 2026 readout

Conference call to be held today, May 15, 2026, at 5:30 a.m. PT / 8:30 a.m. ET

SAN DIEGO, May 15, 2026 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a

ARS Pharmaceuticals Reports First Quarter 2026 Financial Results and Corporate Update

Fri, 15 May 2026 06:00:00 -0400

Q1 2026 total revenue of $22.7 million including neffy® (epinephrine nasal spray) U.S. net product
revenue of $17.5 million

CVS Caremark proposal in final stages of approval process; definitive update anticipated in early June

Sales force expansion to 148 representatives completed

Phase 2b CSU study interim population fully enrolled, and on track for Q4 2026 readout

Conference call to be held today, May 15, 2026, at 5:30 a.m. PT / 8:30 a.m. ET

SAN DIEGO, May 15, 2026 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a

ARS Pharmaceuticals Reports First Quarter 2026 Financial Results and Corporate Update

Fri, 15 May 2026 06:00:00 -0400

Q1 2026 total revenue of $22.7 million including neffy® (epinephrine nasal spray) U.S. net product
revenue of $17.5 million

CVS Caremark proposal in final stages of approval process; definitive update anticipated in early June

Sales force expansion to 148 representatives completed

Phase 2b CSU study interim population fully enrolled, and on track for Q4 2026 readout

Conference call to be held today, May 15, 2026, at 5:30 a.m. PT / 8:30 a.m. ET

SAN DIEGO, May 15, 2026 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a

ARS Pharmaceuticals Reports First Quarter 2026 Financial Results and Corporate Update

Fri, 15 May 2026 06:00:00 -0400

Q1 2026 total revenue of $22.7 million including neffy® (epinephrine nasal spray) U.S. net product
revenue of $17.5 million

CVS Caremark proposal in final stages of approval process; definitive update anticipated in early June

Sales force expansion to 148 representatives completed

Phase 2b CSU study interim population fully enrolled, and on track for Q4 2026 readout

Conference call to be held today, May 15, 2026, at 5:30 a.m. PT / 8:30 a.m. ET

SAN DIEGO, May 15, 2026 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a

ARS Pharmaceuticals Reports First Quarter 2026 Financial Results and Corporate Update

Fri, 15 May 2026 06:00:00 -0400

Q1 2026 total revenue of $22.7 million including neffy® (epinephrine nasal spray) U.S. net product
revenue of $17.5 million

CVS Caremark proposal in final stages of approval process; definitive update anticipated in early June

Sales force expansion to 148 representatives completed

Phase 2b CSU study interim population fully enrolled, and on track for Q4 2026 readout

Conference call to be held today, May 15, 2026, at 5:30 a.m. PT / 8:30 a.m. ET

SAN DIEGO, May 15, 2026 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a

ARS Pharmaceuticals Reports First Quarter 2026 Financial Results and Corporate Update

Fri, 15 May 2026 06:00:00 -0400

Q1 2026 total revenue of $22.7 million including neffy® (epinephrine nasal spray) U.S. net product
revenue of $17.5 million

CVS Caremark proposal in final stages of approval process; definitive update anticipated in early June

Sales force expansion to 148 representatives completed

Phase 2b CSU study interim population fully enrolled, and on track for Q4 2026 readout

Conference call to be held today, May 15, 2026, at 5:30 a.m. PT / 8:30 a.m. ET

SAN DIEGO, May 15, 2026 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a

ARS Pharmaceuticals Reports First Quarter 2026 Financial Results and Corporate Update

Fri, 15 May 2026 06:00:00 -0400

Q1 2026 total revenue of $22.7 million including neffy® (epinephrine nasal spray) U.S. net product
revenue of $17.5 million

CVS Caremark proposal in final stages of approval process; definitive update anticipated in early June

Sales force expansion to 148 representatives completed

Phase 2b CSU study interim population fully enrolled, and on track for Q4 2026 readout

Conference call to be held today, May 15, 2026, at 5:30 a.m. PT / 8:30 a.m. ET

SAN DIEGO, May 15, 2026 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a